VKTX Stock Recent News

Viking Therapeutics' VK2735, a GLP-1 candidate, has driven significant share price gains but faces stiff competition from Eli Lilly and Novo Nordisk. Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future trials. VK2735's subcutaneous and oral formulations show promising weight loss results and safety, with Phase 3 and Phase 2 trials soon to be underway.

VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2025 Results Conference Call April 23, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Asim Rana - Truist Securities Mike Ulz - Morgan Stanley Ryan Deschner - Raymond James Jay Olson - Oppenheimer Hardik Parikh - JPMorgan Mayank Mamtani - B. Riley Securities Annabel Samimy - Stifel Roger Song - Jefferies Andy Hsieh - William Blair Biren Amin - Piper Sandler Thomas Smith - Leerink Partners George Farmer - Scotiabank Yale Jen - Laidlaw & Company Jeet Mukherjee - BTIG Operator Welcome to the Viking Therapeutics First Quarter 2025 Financial Results Conference Call.

Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735 Strong Quarter-End Cash Position of $852 Million SAN DIEGO , April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate developments.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates.  The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.

Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look for terrific stocks to invest in while they are down.

VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.

Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.